U.S. Wireless Telecom Stock News

Many investors are wondering if Masimo at around $135 a share is a bargain in disguise or a value trap. This stock has been on a lot of watchlists lately. Despite a strong long term track record in medical technology, the stock is down about 2.9% over the last week, 7.7% over the last month, and roughly 20.5% over the past year. This has reset expectations and risk perceptions for many shareholders. Recent headlines have focused on Masimo's ongoing push into non invasive monitoring...

If you are wondering whether PayPal Holdings is a bargain or a value trap at today’s price, you are not alone. That is exactly what we are going to unpack. The stock is trading around $60.18, down 2.4% over the last week and about flat over the past month, but still sitting roughly 30% lower year to date and more than 70% below its 5 year level. Recent attention around PayPal has focused on its push to reinvigorate growth through new payment tools and partnerships, alongside ongoing efforts...

If you are wondering whether Marathon Petroleum still offers good value after its big run, or if you might be turning up late to the party, this breakdown will help you decide whether the current price makes sense. Even after a recent pullback, with the share price down 8.8% over the last week and 11.0% over the past month, Marathon is still up 23.3% year to date and 381.5% over five years, which highlights how strong the longer term story has been. Recent headlines have focused on Marathon...

Bristol Myers Squibb recently reported a series of oncology milestones, including FDA priority review for Opdivo plus AVD in advanced classical Hodgkin lymphoma and U.S. approval of Breyanzi for relapsed or refractory marginal zone lymphoma, alongside new hematology data at the ASH Annual Meeting. At the same time, the company extended its 94-year dividend record with a US$0.63 quarterly common dividend and secured new antibody-discovery collaborations, underscoring how late-stage...

Johnson & Johnson recently received U.S. FDA approval for RYBREVANT FASPRO™, the first subcutaneous amivantamab-based therapy for EGFR‑mutated non‑small cell lung cancer, covering all existing RYBREVANT® indications. The approval, backed by Phase 3 data showing at least comparable pharmacokinetics and signals of longer survival versus intravenous dosing, underscores how J&J is pairing oncology innovation with treatment convenience and potential system‑wide efficiency gains. We’ll now examine...

Hess Midstream recently issued full-year 2026 guidance, forecasting net income of US$650 million to US$700 million and outlining expected gathering, processing, and terminal volumes across its Bakken-focused midstream network. The company also reshaped its board leadership by appointing existing director Kristi McCarthy as Chair and adding Chevron executive Barbara Harrison, highlighting the deepening alignment with its largest customer and partner. Next, we’ll examine how this new 2026...

Wondering if Thermo Fisher Scientific is still worth buying at these levels, or if the market has already priced in the upside? This breakdown will help you see where the real value might be hiding. The stock is up 7.7% year to date and 9.3% over the last year, even after a recent pullback of around 2.8% over the past week and 2.3% over the last month. This suggests sentiment is positive but not euphoric. Recently, investors have been reacting to Thermo Fisher's ongoing role in high growth...

Wondering if Ecolab at around $261 a share is still a smart buy, or if the easy money has already been made? Let us unpack what the market might be pricing in and where the value really sits. The stock is up 1.7% over the last week, 2.5% over the past month, and 13.4% year to date, with a strong 87.4% gain over three years and 29.7% over five, which suggests investors have been steadily bidding up its quality story. Recently, investors have been paying closer attention to Ecolab as demand...

Ubiquiti Inc. recently reported that long-serving director Ronald A. Sege, who joined the board in 2012 and chaired its nominating and corporate governance committee while also serving on the audit and compensation committees, passed away on November 30, 2025, leaving his Class II board seat vacant. His death has reduced the audit committee to two independent directors, putting Ubiquiti out of compliance with New York Stock Exchange rules that require at least three independent audit...

Core Natural Resources (CNR) just cleared a major operational overhang, bringing its Leer South longwall mine back online after a combustion related shutdown and stabilizing productivity at West Elk, which may support a cleaner 2026 earnings picture. See our latest analysis for Core Natural Resources. The restart at Leer South has helped steady sentiment after a bruising stretch. A 90 day share price return of 8.46% contrasts with a weaker year to date and one year total shareholder return,...

Netflix (NFLX) has quietly slipped over the past month, even as its underlying business continues to generate solid growth in revenue and earnings. That disconnect is where the investment story gets interesting. See our latest analysis for Netflix. Over the past year Netflix’s share price has swung from strong gains to a sharp 1 month pullback of 16.9%, even as its 3 year total shareholder return of 218.4% shows that long term momentum remains very much intact. If Netflix’s shift into games...

SoFi Technologies (SOFI) has pulled back about 5% in the past week and 14% over the past 3 months, even though the stock is still up roughly 79% year to date. See our latest analysis for SoFi Technologies. The recent pullback looks more like a pause than a trend reversal, with SoFi’s 1 year total shareholder return of 68.13% and exceptional 3 year total shareholder return of 451.75% still signaling strong underlying momentum and improving sentiment around its growth story. If SoFi’s run has...

Ethos recently announced a partnership with Aflac Incorporated to distribute Aflac’s supplemental cancer insurance through Ethos’s fully digital platform, giving consumers quicker access to cash benefits for cancer-related expenses with no deductibles and simplified claims. The deal highlights how Aflac can plug its specialized supplemental health products into a third-party insurtech ecosystem, potentially broadening reach without rebuilding its own end-to-end digital distribution. We’ll...

Wondering if KeyCorp is still worth a closer look after its recent run, or if the value has already been priced in? This breakdown is designed to help you decide with confidence. The stock has climbed 0.5% in the last week, 21.0% over the past month and is now up 22.5% year to date, adding to a 29.7% gain over 1 year, 44.0% over 3 years and 63.4% over 5 years. That kind of momentum has been supported by a steady drip of positive sentiment around regional banks, regulatory clarity and...

Recent analyst upgrades, combined with record bookings and strong earnings, have pushed Trane Technologies (TT) back into the spotlight as investors reassess how its data center and sustainability strategy might support future returns. See our latest analysis for Trane Technologies. Even with the latest upgrades and upbeat data center narrative, the shares have cooled off in the past month, with a 30 day share price return of negative 6.08 percent from around $382.30. That compares with a...

Seagate Technology Holdings (STX) just clinched a spot in the Nasdaq 100, a shift that could pull in fresh index fund money while spotlighting its AI driven storage story and recently improved dividend. See our latest analysis for Seagate Technology Holdings. That Nasdaq 100 promotion caps an explosive run, with a year to date share price return above 220% and a three year total shareholder return above 500%, even after a sharp recent pullback as traders lock in AI driven gains. If Seagate’s...

Fresh analysis of Deckers Outdoor (DECK) is putting its fundamentals under the microscope, as sluggish constant currency growth and a below industry operating margin start to shape how investors view the stock. See our latest analysis for Deckers Outdoor. Despite a solid 26.85% 1 month share price return and recent excitement around its brands, the stock still carries a steep year to date share price loss. However, the 3 year total shareholder return remains strongly positive, hinting that...

Fresh analyst upgrades and reaffirmed Buy ratings have pushed MKS (MKSI) back onto investors’ radar, as the semiconductor technology supplier sees confidence in its outlook rise alongside expectations for continued earnings momentum. See our latest analysis for MKS. Even after a sharp pullback last week, with a 7 day share price return of negative 11.42 percent, MKS is still up meaningfully this year thanks to a 40.26 percent year to date share price return and a 43.96 percent 1 year total...

Relay Therapeutics (RLAY) just put fresh clinical data for its PI3Kα inhibitor zovegalisib in the spotlight at the San Antonio Breast Cancer Symposium, and the update helps clarify how the stock’s story is evolving. See our latest analysis for Relay Therapeutics. That backdrop helps explain why, even after a 5.31% one day pullback to $8.03, Relay’s 30 day share price return is 23.35% and its year to date share price return sits at 86.74%. The 3 year total shareholder return of negative 47.03%...

If you are wondering whether Bank of New York Mellon is still worth buying after its huge run, or if the easy money has already been made, this article will walk through whether the current price still stacks up against its fundamentals. Even after a recent 4.1% pullback over the last week, the stock is still up 6.4% over the past month, 46.7% year to date and 53.1% over the last year. Multi year gains above 170% point to a substantial re rating in how the market views the business. Those...

NeoGenomics, Inc. recently secured a legal win as Natera dropped its appeal over invalidated patent claims, while also presenting new data on its RaDaR MRD assay and myeloid comprehensive genomic profiling at major cancer conferences in December 2025. This combination of a cleared legal overhang and fresh clinical evidence for key oncology tests underscores how intellectual property and scientific validation can work together to support NeoGenomics’ competitive position. We’ll now examine...

If you are wondering whether Mastercard at around $565 a share is still a smart buy, or if most of the upside has already been priced in, this breakdown is for you. The stock has climbed 4.9% over the last week, 5.3% over the past month, and is up 8.2% year to date, building on 9.4% over 1 year and 66.5% and 76.7% over 3 and 5 years respectively. Recent headlines have focused on Mastercard’s continued push into real time payments and open banking partnerships, as well as regulatory...

Cloudflare (NET) has been on a volatile ride lately, with the stock giving back some gains even after strong revenue and earnings momentum. That disconnect between business performance and price is what investors are now parsing. See our latest analysis for Cloudflare. After a big run earlier in the year, Cloudflare’s latest 1 week share price pullback and a 90 day share price return of minus 14.38 percent look more like a pause within a still powerful 1 year total shareholder return of 75.46...

If you are wondering whether MasTec is still a smart buy after its big run, you are not alone. This breakdown is here to cut through the noise. The stock has pulled back about 10.2% over the last week, but it is still up 7.4% over the past month, 49.5% year to date, and 58.5% over the last year. That combination hints at strong momentum and a shifting risk reward profile. Behind those moves, investors have been reacting to MasTec’s expanding backlog in energy and infrastructure projects,...